A Phase 2/3 interventional study of Atropine 0.05% Eye drops and Placebo ophthalmic solution in Myopia, sponsored by Mansoura University. Not yet recruiting. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Mansoura University · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.
Among the 54 studies testing atropine in Myopia, this one is the 45th largest by planned enrollment, is one of 5 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 15 of the 23 other live ones, and was the 45th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages 5–11
Ohio State University · Sites in United States
Ages 6–11 · Healthy volunteers
IDB VisionCare SDN BHD · Sites in Malaysia
Ages 5–10
Ocus Innovation Ireland Limited · Sites in Albania, Italy, Poland and 2 more countries
Ages 3–17
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
By country, each count listing its studies:
Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 16 · Phase 4 8
First in 2005; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 45 is below the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 144 across the 54 interventional studies. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
Mansoura University is the lead sponsor of 1,121 studies on the registry; 183 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Mansoura University has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
8 of the studies testing atropine in Myopia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07329777Phase 3IDB VisionCare SDN BHDAtropine in the Treatment of Myopia Study in Malaysia | 2027-09 |
| NCT07164092Phase 3Mansoura UniversityEfficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center | 2027-09 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
| NCT05379855Eye & ENT Hospital of Fudan UniversityA-eyedrops on Ocular Alignment and Binocular Vision | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 54 studies testing atropine in Myopia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial aims to evaluate the efficacy and safety of low-dose topical atropine sulphate (0.05%), a non-selective muscarinic antagonist, in slowing the progression of myopia and ocular axial elongation in children. The study will be conducted at Mansoura Ophthalmic Center, Mansoura University, Egypt, from October 2025 to october 2027.
Eligible participants are myopic children attending the outpatient clinic during the study period. Participants will be stratified into three groups according to baseline myopia severity (low, moderate, and high). Each child will be randomized to receive one drop of atropine 0.05% in one eye and one drop of placebo in the fellow eye nightly for 24 months. The allocation of treatment to right or left eye will be randomized to avoid laterality bias.
Study Outcomes
Primary Outcome
o Change in ocular axial length (AL) from baseline to 24 months, measured with a NIDEK AL-scan optical biometer (average of five readings within a deviation of ≤0.05 mm). This parameter was used for sample size estimation.
Secondary Outcomes
The primary endpoint of this trial is the change in ocular axial length (AL) over 24 months, analyzed as a paired comparison between the atropine-treated and placebo-treated eyes within each child.
Sample size estimation was based on previously published data reporting mean axial elongation of 0.115 ± 0.11 mm in atropine-treated eyes compared with 0.303 ± 0.12 mm in placebo-treated eyes, yielding a mean difference of 0.188 mm. Assuming an inter-eye correlation of 0.6, the standard deviation of the paired difference is estimated at approximately 0.10 mm, giving an effect size of d = 1.88. Using a two-tailed paired t-test with α = 0.05 and 90% power, the minimum required sample size is 12 children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The randomized eye will receive one drop of atropine sulphate 0.05% nightly for 24 months.
Drug: Atropine 0.05% Eye drops
The fellow eye will receive one drop of placebo (vehicle solution without active drug) nightly for 24 months.
Drug: Placebo ophthalmic solution
The randomized eye will receive one drop of atropine sulphate 0.05% nightly for 24 months.
The fellow eye will receive one drop of placebo (vehicle solution without active drug) nightly for 24 months.
Change in ocular axial length (AL)
Change in ocular axial length (AL) from baseline to 24 months, measured with a NIDEK AL-scan optical biometer (average of five readings within a deviation of ≤0.05 mm). This parameter was used for sample size estimation
Time frame: 2 years
Change in spherical equivalent refraction (SER
Change in spherical equivalent refraction (SER), measured by cycloplegic autorefraction using a Topcon KR-800 autorefractor after standard cycloplegia with cyclopentolate 1%.
Time frame: 24 months
Best-corrected distance visual acuity (BCVA).
Time frame: 24 months
No study locations are listed for this record.
Plan to share: Undecided — I have not decided yet
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Sep 2027, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atropine